Table 2.
Association between gender-affirming hormone therapy and headache status among 273 transfeminine adolescents and 490 transmasculine adolescents.
| Group: | with headache | without headache | overall sample | Odds Ratio |
|---|---|---|---|---|
|
| ||||
| Transfeminine, n (%) | ||||
|
| ||||
| treated with estrogen | 9 (7) | 114 (93) | 123 (45) | 5.8 (1.24–27.6)* |
| untreated | 2 (1) | 148 (99) | 150 (55) | |
|
|
||||
| Total | 11 (4) | 262 (96) | 273 (100) | |
|
| ||||
| Transmasculine n (%) | ||||
|
| ||||
| treated with testosterone | 28 (12) | 199 (88) | 227 (46) | 2.71 (1.37–5.4)** |
| untreated | 13 (5) | 250 (95) | 263 (54) | |
|
|
||||
| Total | 41 (8) | 449 (92) | 490 (100) | |
95% confidence interval Woolf exact method, significance 2‐sided Fisher’s exact test.
*
p-value is 0.026
**
p-value is 0.005.